Researchers Gain New Insights into How Tumor Cells Are Fed
Shows promise for development of anti-tumor drugs
Philadelphia, PA, August 8, 2011 – Researchers have gained a new understanding of the way in which growing tumors are fed and how this growth can be slowed via angiogenesis inhibitors that eliminate the blood supply to tumors. This represents a step forward towards developing new anti-cancer drug therapies. The results of this study have been published today in the September issue of The American Journal of Pathology.
“The central role of capillary sprouting in tumor vascularization makes it an attractive target for anticancer therapy. Our observations suggest, however, that targeting just this mode of blood vessel formation may not be sufficient to result in a significant antitumor effect,” commented lead investigators Sándor Paku, PhD, Semmelweis University, Budapest, and Balazs Dome, MD, PhD, Medical University of Vienna.
Investigators from the Semmelweis University, the National Institute of Oncology, and the National Koranyi Institute of Pulmonology, Budapest, Hungary, and the Medical University of Vienna, Vienna, Austria, used electron and confocal microscopy to examine tumor tissue in mice in which malignant tumor cells had been introduced. They proposed a novel mechanism for the development of tissue pillars (the most characteristic feature of intussusceptive angiogenesis, in which a vessel folds into itself to form two vessels). Moreover, they demonstrated a significant increase in pillar formation after treatment with the angiogenesis inhibitor vatalanib. Their observations support the notion that inhibition of just a single tumor vascularization mechanism can trigger alternative ones.
Prior to this study, the mechanism of pillar formation had not been fully understood. Investigation revealed a progression of events that generates a connection between the processes of endothelial bridging and intussusceptive angiogenesis resulting in rapid pillar formation from pre-existing building blocks. To describe this mechanism of pillar formation the group coined the term “inverse sprouting.”
“It is well established now that tumors can obtain sufficient blood supply from alternative vascularization mechanisms (such as intussusceptive angiogenesis) to grow without capillary sprouting (known as the key mode of new vessel formation in cancer). Therefore, antiangiogenic therapies should be tailored depending on the angiogenic phenotype in each single tumor, and the targeting of non-sprouting angiogenic mechanisms in cancer seems to be a rational strategy. Our study provides new understanding of cancer-induced intussusceptive angiogenesis and may serve as a basis for the development of novel drugs targeting this type of blood vessel formation."
The article is “A New Mechanism for Pillar Formation during Tumor-Induced Intussusceptive Angiogenesis” by Sándor Paku,Katalin Dezsö, Edina Bugyik,József Tóvári,József Tímár, Péter Nagy,Viktoria Laszlo, Walter Klepetko, and Balázs Döme (doi: 10.1016/j.ajpath.2011.05.033). It will appear in The American Journal of Pathology, Volume 179, Issue 3 (September 2011) published by Elsevier.
# # #
Notes for the editors
Full text of the article is available to credentialed journalists upon request; contact David Sampson at +1 215 239 3171 email@example.com. Journalists wishing to interview the authors may contact Dr. Balazs Dome, Translational Thoracic Oncology Laboratory, Department of Thoracic Surgery, Medical University of Vienna, at +36 203131869 or +43 6764865370 or via email at firstname.lastname@example.org.
About The American Journal of Pathology
The American Journal of Pathology ( http://ajp.amjpathol.org), official journal of the American Society for Investigative Pathology, seeks to publish high-quality, original papers on the cellular and molecular biology of disease. The editors accept manuscripts that advance basic and translational knowledge of the pathogenesis, classification, diagnosis, and mechanisms of disease, without preference for a specific analytic method. High priority is given to studies on human disease and relevant experimental models using cellular, molecular, animal, biological, chemical, and immunological approaches in conjunction with morphology.
The leading global forum for reporting quality original research on cellular and molecular mechanisms of disease, The American Journal of Pathology is the most highly cited journal in Pathology with an Impact Factor of 5.224 according to Thomson Reuters Journal Citation Reports® 2010.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence, and ClinicalKey — and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).Media contacts
Executive Publisher, Elsevier
+1 215 239 3171
Dr. John Nelson
The American Journal of Pathology
+1 301 634 7953